LYSINE BIOTECH Private Limited (LBPL) is an IP driven company committed to formulation of drugs, vaccines, diagnostics of infectious agents (RT-PCR, rapid test antigen & ELISA) and range from DNA and Protein sequence target specific (N-terminal and C-terminal) based on antibody epitope prediction for rapid test antigen and antibody to peptide/protein drugs up to vaccines as well as gene therapy products.
Technical strength: Bioinformatics, Biotechnology, organic and biochemistry, three dimensional (3D) computer graphics for modelling, bio images and artificial intelligence.
Target identification and validation, hit identification, hit to lead, lead optimization, and IND enabling studies with integration into development.
Strong focus on IP protection and safety.
Strong capabilities in new scientific platforms including gene therapies, Targeted Protein Degradation and bi-specific antibody conjugates.
Expertise across therapeutic areas: Diabetics, oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolism, inflammation, and rare/orphan diseases.
AIC-CCMB- Cohort-B of Standard Incubation Program, The product development and innovation centre LYSINE BIOTECH PRIVATE LIMITED company is located in 3rd Floor ATAL INCUBATION CENTRE- CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY (AIC-CCMB), Medical Biotechnology Complex, CCMBAnnex-2, IDA Uppal, Genpact Road, Hyderabad, Telangana, INDIA. Supported by Atal Incubation Centre under the Atal Innovation Mission (AIM) of National Institution for Transforming India (NITI Aayog). Innovations in life sciences are critical to Make in India